Pregabalin for Abdominal Pain From Adhesions
Abdominal Pain, Surgical Adhesions
About this trial
This is an interventional treatment trial for Abdominal Pain focused on measuring abdominal pain, surgical adhesions
Eligibility Criteria
Inclusion Criteria: Must have history of prior surgery and documented adhesions during laparoscopy or open laparotomy within 5 years Must have undergone an evaluation to exclude other causes of abdominal pain Abdominal pain must be present for greater than three months duration Exclusion Criteria: Patients that are pregnant or breast feeding Prior treatment with gabapentin, pregabalin or demonstrated sensitivity to these drugs Patients who are immunocompromised Patients with significant hepatic or renal insufficiency, or any significant hematologic disorder History of illicit alcohol or drug abuse within one year Documented serious or unstable medical or psychological condition Malignancy within the past 5 years other than in situ squamous cell carcinoma of the skin
Sites / Locations
- Henry Ford Health System
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Pregabalin 150 or 300 mg daily for severe abdominal pain from adhesions
Look alike placebo 150 or 300 mg daily for severe abdominal pain from adhesions
Patients were randomly assigned to active drug 75-150 mg of pregabalin po BID for 7 weeks followed by a 1 week wash out phase and then were given 150 mg of pregabalin BID for an additional 4 weeks. Daily pain and sleep scores were reported by the patient throughout the study.
Patients were randomly assigned to look alike placebo 75 or 150 mg po BID for 7 weeks followed by a 1 week wash out phase and then were given 150 mg of pregabalin BID for an additional 4 weeks. Daily pain and sleep scores were reported by the patient throughout the study.